 |
Glen MacDonald,
Ph.D. Chief Scientific Officer & Vice President
, Operations
Dr. Glen MacDonald
is Viventia’s most senior research executive
and is responsible for the Company’s overall
research and operational activities at Viventia's
Winnipeg facility. In regard to research, Dr. MacDonald
oversees the management and implementation of Viventia’s
core technology platforms: Hybridomics™, ImmunoMine™,
UnLock™ and Armed Antibodies™, as well
as Viventia’s Process Sciences Department. In
addition, Dr. MacDonald is responsible for the operational
areas involved in the cGMP manufacture of Viventia’s
clinical products. Dr. MacDonald joined Viventia Biotech
in July, 1997 and has held positions of increasing
responsibility within the company becoming the Vice
President, Research in 2004. Prior to joining Viventia
Biotech, Dr. MacDonald was with The University of
Manitoba Cancer Treatment Research Foundation, The
University of North Carolina, Chapel Hill, and the
Ontario Cancer Institute, Princess Margaret Hospital.
Dr. MacDonald holds a Ph.D. from
The University of Manitoba and has published in the
areas of monoclonal antibodies, graft-versus-host
disease, lupus and apoptosis.
Back
to Executive Team
|
